Finding treatments for dry age-related macular degeneration requires a large-scale, collaborative, systems biology approach.
Dry AMD, which currently has no treatment options, is a leading cause of blindness in people aged 65 years and older.
A report published in Nature Communications proposed researchers use a broad approach, integrating data available from clinical registries and biology to develop models and possibly treatments for dry AMD, a press release from the National Eye Institute said.
“This approach would integrate basic, genomic, preclinical, medical, pharmacological and clinical data into mathematical models of pathological processes at different stages of dry AMD in order to ask how relevant individual components act together within the living system,” Joan W. Miller, MD, chair of Harvard Medical School’s Department of Ophthalmology, said in the NEI release.
Handa JT, et al. Nat Commun. 2019;doi:10.1038/s41467-019-11262-1.